Robertson Stephens Wealth Management LLC Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Robertson Stephens Wealth Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 16.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 25,948 shares of the company’s stock after selling 5,157 shares during the period. Robertson Stephens Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,303,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the 4th quarter worth about $29,000. Conquis Financial LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Barclays dropped their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Raymond James Financial reduced their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Stock Down 1.8%

Shares of NYSE JNJ opened at $152.38 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock’s 50-day simple moving average is $154.03 and its 200-day simple moving average is $153.69. The firm has a market cap of $366.65 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 2.35 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.41%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.